JP6778697B2 - 癌の治療のための免疫療法薬としての、組み換えマイコバクテリウム - Google Patents
癌の治療のための免疫療法薬としての、組み換えマイコバクテリウム Download PDFInfo
- Publication number
- JP6778697B2 JP6778697B2 JP2017557195A JP2017557195A JP6778697B2 JP 6778697 B2 JP6778697 B2 JP 6778697B2 JP 2017557195 A JP2017557195 A JP 2017557195A JP 2017557195 A JP2017557195 A JP 2017557195A JP 6778697 B2 JP6778697 B2 JP 6778697B2
- Authority
- JP
- Japan
- Prior art keywords
- immunotherapeutic
- immunotherapeutic agent
- agent according
- drug
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01005—Urease (3.5.1.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
(a)免疫応答を誘発させることが可能なドメイン、および
(b)ファゴリソソームエスケープドメイン
を含む融合ポリペプチドをコードする組み換え核酸分子を含む、固形腫瘍の治療での免疫療法薬としての使用のための、組み換えマイコバクテリウム細胞である。
(a)免疫応答を誘発させることが可能なドメイン、および
(b)ファゴリソソームエスケープドメイン
を含む融合ポリペプチドをコードする組み換え核酸分子を含む組み換えマイコバクテリウム細胞を、前記対象に投与するステップを含む。
3.1 臨床プロトコル
組み換えBCG(上記に定義)は、現在のところ、膀胱への滴下によって、フェーズI/II臨床試験の一部として臨床で適用されている。臨床試験フェーズI/IIは、標準的なBCG治療後に再発性の非筋肉浸潤性膀胱癌を有するヒト患者における、rBCGの膀胱内滴下の安全性および有効性の評価を目的とする。rBCGは、15回の毎週の滴下で膀胱に投与される(誘導段階:滴下1〜6、維持3ヶ月:滴下7〜9、維持6ヶ月:滴下10〜12、維持12ヶ月:滴下13〜15)。
・投与量レベル1:rBCGの1〜19.2×108CFU
・投与量レベル−1:rBCGの1〜19.2×107CFU
臨床試験は、現在のところ、スイス(Basel,Geneva,Chur,Bern,Bellinzona,St.Gallen)の治験施設において、フェーズIのフレーム内で、患者を募っている。
Claims (12)
- ヒト対象における膀胱癌の治療のための免疫療法薬であって、
(a)配列番号2のaa.41〜aa.51のアミノ酸配列を含む、免疫応答を誘発させることが可能なドメイン、および
(b)(i)配列番号1に示されるヌクレオチド211〜1722を含むヌクレオチド配列、
(ii)(i)由来の配列と同一のアミノ酸配列をコードするヌクレオチド配列、および
(iii)(i)または(ii)由来の配列とストリンジェントな条件下でハイブリダイズするヌクレオチド配列、
から選択される核酸分子によってコードされる、リステリアのファゴリソソームエスケープドメイン
を含む融合ポリペプチドをコードする組み換え核酸分子を含む、
Danish株のPrague亜型由来のウレアーゼ欠乏組み換えMycobacterium bovis BCG細胞を含み、
前記治療は、膀胱への膀胱内滴下による、前記免疫療法薬の局所投与を含む、
免疫療法薬。 - 請求項1に記載の免疫療法薬であって、
前記の組み換え核酸分子は、いかなる機能性選択マーカーも含まない、
免疫療法薬。 - 請求項1または2に記載の免疫療法薬であって、
前記免疫療法薬は、外科的処置後に、膀胱への膀胱内滴下によって投与される、
免疫療法薬。 - 請求項1から3のいずれか一項に記載の免疫療法薬であって、
前記膀胱癌は、非浸潤性膀胱癌、非浸潤性乳頭癌(Ta)、または、上皮下結合組織に侵入する腫瘍(T1)である、
免疫療法薬。 - 請求項4に記載の免疫療法薬であって、
前記非浸潤性膀胱癌が、上皮内癌(T cis )である、
免疫療法薬。 - 請求項1から5のいずれか一項に記載の免疫療法薬であって、
標準的なBCGによって以前に治療されたことのない、新たに診断された、または、再発性の膀胱癌を有する患者を治療するための、
免疫療法薬。 - 請求項1から5のいずれか一項に記載の免疫療法薬であって、
標準的なBCGによって以前に治療されたことのある、再発性の膀胱癌を有する患者を治療するための、
免疫療法薬。 - 請求項1から7のいずれか一項に記載の免疫療法薬であって、
前記免疫療法薬は、(i)6回の毎週の滴下による誘導段階、3ヶ月後の3回の毎週の滴下による第一の維持段階、6ヶ月後の3回の滴下による第二の維持段階、および、12ヶ月後の3回の滴下による第三の維持段階の間の、毎週の滴下を伴うスケジュールに従って、膀胱に投与される、
免疫療法薬。 - 請求項1から8のいずれか一項に記載の免疫療法薬であって、
前記免疫療法薬は、投与あたり106〜1010CFUの投与量で使用される、
免疫療法薬。 - 請求項1から9のいずれか一項に記載の免疫療法薬であって、
前記免疫療法は、前記組み換えMycobacterium bovis細胞の非腫瘍部位特異的な投与と組み合わせられる、
免疫療法薬。 - 請求項1から10のいずれか一項に記載の免疫療法薬であって、
投与の部位において、限局性および/または多巣性リンパ性浸潤を得るための、
免疫療法薬。 - 請求項11に記載の免疫療法薬であって、
CD4およびCD8T細胞による、限局性および/または多巣性の組織浸潤を得るための、
免疫療法薬。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15166206.1 | 2015-05-04 | ||
EP15166206.1A EP3090757A1 (en) | 2015-05-04 | 2015-05-04 | Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer |
US201562387407P | 2015-12-23 | 2015-12-23 | |
US62/387,407 | 2015-12-23 | ||
PCT/EP2016/059872 WO2016177717A1 (en) | 2015-05-04 | 2016-05-03 | Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018520643A JP2018520643A (ja) | 2018-08-02 |
JP6778697B2 true JP6778697B2 (ja) | 2020-11-04 |
Family
ID=53054880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017557195A Active JP6778697B2 (ja) | 2015-05-04 | 2016-05-03 | 癌の治療のための免疫療法薬としての、組み換えマイコバクテリウム |
Country Status (25)
Country | Link |
---|---|
US (2) | US10525118B2 (ja) |
EP (2) | EP3090757A1 (ja) |
JP (1) | JP6778697B2 (ja) |
KR (1) | KR102667859B1 (ja) |
CN (1) | CN107864656A (ja) |
AU (1) | AU2016258885B2 (ja) |
BR (1) | BR112017023747A2 (ja) |
CA (1) | CA2984602C (ja) |
CU (1) | CU20170138A7 (ja) |
CY (1) | CY1123754T1 (ja) |
DK (1) | DK3291831T3 (ja) |
EA (1) | EA036492B1 (ja) |
ES (1) | ES2845724T3 (ja) |
HK (1) | HK1247574A1 (ja) |
HR (1) | HRP20210107T1 (ja) |
HU (1) | HUE052711T2 (ja) |
IL (1) | IL255303B (ja) |
LT (1) | LT3291831T (ja) |
MX (1) | MX2017014142A (ja) |
PH (1) | PH12017502011A1 (ja) |
PL (1) | PL3291831T3 (ja) |
PT (1) | PT3291831T (ja) |
RS (1) | RS61333B1 (ja) |
SI (1) | SI3291831T1 (ja) |
WO (1) | WO2016177717A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117098848A (zh) * | 2021-03-22 | 2023-11-21 | 科列普斯生物医药科技有限公司 | 新型耻垢分枝杆菌重组菌株及其应用 |
IL310225A (en) * | 2021-07-22 | 2024-03-01 | Serum Life Science Europe Gmbh | Recombinant MYCOBACTERIUM as an immunotherapeutic agent for the second-line treatment of bladder carcinoma |
EP4122491A1 (en) * | 2021-07-22 | 2023-01-25 | Vakzine Projekt Management GmbH | Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733151A (en) | 1996-08-23 | 1998-03-31 | Edsall; David | Electrical clamping connection device |
KR101101263B1 (ko) | 2003-04-23 | 2012-01-04 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 개선된 효능을 갖는 결핵 백신 |
EP1649869A1 (en) * | 2004-10-21 | 2006-04-26 | Vakzine Projekt Management GmbH | Combination of a recombinant mycobacterium and a biologically active agent as a vaccine |
AU2014210617B2 (en) * | 2004-10-21 | 2016-07-21 | Vakzine Projekt Management Gmbh | Combination of a recombinant mycobacterium and a biologically active agent as a vaccine |
PL3360569T3 (pl) | 2010-09-20 | 2020-07-27 | Vakzine Projekt Management Gmbh | Rekombinowane Mycobacterium jako szczepionka do stosowania u ludzi |
SG191332A1 (en) * | 2010-12-21 | 2013-07-31 | Max Planck Gesellschaft | Recombinant mycobacterium as a vaccine |
US9678075B2 (en) * | 2011-06-10 | 2017-06-13 | Deutsches Krebsforschungszentrum | Prediction of recurrence for bladder cancer by a protein signature in tissue samples |
EP2620159A1 (en) * | 2012-01-24 | 2013-07-31 | Institut Pasteur | Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
-
2015
- 2015-05-04 EP EP15166206.1A patent/EP3090757A1/en not_active Withdrawn
-
2016
- 2016-05-03 DK DK16724315.3T patent/DK3291831T3/da active
- 2016-05-03 CN CN201680034463.7A patent/CN107864656A/zh active Pending
- 2016-05-03 HU HUE16724315A patent/HUE052711T2/hu unknown
- 2016-05-03 BR BR112017023747-4A patent/BR112017023747A2/pt active Search and Examination
- 2016-05-03 LT LTEP16724315.3T patent/LT3291831T/lt unknown
- 2016-05-03 AU AU2016258885A patent/AU2016258885B2/en active Active
- 2016-05-03 EP EP16724315.3A patent/EP3291831B1/en active Active
- 2016-05-03 MX MX2017014142A patent/MX2017014142A/es unknown
- 2016-05-03 ES ES16724315T patent/ES2845724T3/es active Active
- 2016-05-03 SI SI201631067T patent/SI3291831T1/sl unknown
- 2016-05-03 RS RS20210059A patent/RS61333B1/sr unknown
- 2016-05-03 KR KR1020177034007A patent/KR102667859B1/ko active IP Right Grant
- 2016-05-03 CA CA2984602A patent/CA2984602C/en active Active
- 2016-05-03 PT PT167243153T patent/PT3291831T/pt unknown
- 2016-05-03 JP JP2017557195A patent/JP6778697B2/ja active Active
- 2016-05-03 CU CUP2017000138A patent/CU20170138A7/es unknown
- 2016-05-03 PL PL16724315T patent/PL3291831T3/pl unknown
- 2016-05-03 US US15/571,415 patent/US10525118B2/en active Active
- 2016-05-03 EA EA201792412A patent/EA036492B1/ru not_active IP Right Cessation
- 2016-05-03 WO PCT/EP2016/059872 patent/WO2016177717A1/en active Application Filing
-
2017
- 2017-10-29 IL IL255303A patent/IL255303B/en unknown
- 2017-11-03 PH PH12017502011A patent/PH12017502011A1/en unknown
-
2018
- 2018-05-31 HK HK18107179.8A patent/HK1247574A1/zh unknown
-
2019
- 2019-11-19 US US16/688,371 patent/US11426453B2/en active Active
-
2021
- 2021-01-15 CY CY20211100030T patent/CY1123754T1/el unknown
- 2021-01-21 HR HRP20210107TT patent/HRP20210107T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021088568A (ja) | 免疫原性抗炎症組成物 | |
Rentsch et al. | Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy | |
BRPI0905725B1 (pt) | vacina e embalagem farmacêutica | |
TW201723171A (zh) | 基於李斯特菌屬之免疫原性組成物及其於癌症預防與治療中之使用方法 | |
US11426453B2 (en) | Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer | |
JP2018537511A (ja) | リステリア系免疫療法およびその使用方法 | |
JP2012501189A (ja) | 癌、結核、および線維化肺疾患の治療のためのマイコバクテリアの免疫原性を高める方法および組成物 | |
CN105816866B (zh) | 免疫原性抗炎组合物 | |
Perez Sanchez et al. | Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate | |
EP3360569B1 (en) | Recombinant mycobacterium as vaccine for use in humans | |
EP4122491A1 (en) | Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma | |
Zhou et al. | Low-dose docetaxel enhances the anti-tumour efficacy of a human umbilical vein endothelial cell vaccine | |
US20220160858A1 (en) | Recombinant Mycobacterium as an Immunotherapeutic Agent for the Treatment of Cancer | |
WO2023001895A1 (en) | Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma | |
Aremu et al. | Immunotherapy for head and neck cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200203 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200928 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201012 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6778697 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |